Evolution of knowledge related to breast cancer heterogeneity: A 25-year retrospective

Journal of Clinical Oncology

Volumn 26, Issue 13, 2008, Pages 2068-2071

  Fisher, Bernard ^a   Redmond, Carol K ^b   Fisher, Edwin R ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; PHENYLALANINE; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; ESTROGEN SYNTHESIS; GENETIC HETEROGENEITY; HORMONAL THERAPY; HUMAN; INCIDENCE; LYMPH NODE DISSECTION; MENOPAUSE; NOTE; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER STAGING; CHEMISTRY; EVIDENCE BASED MEDICINE; FEMALE; HISTORY; LYMPH NODE METASTASIS; MASTECTOMY; PATHOLOGY; PATIENT SELECTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EVIDENCE-BASED MEDICINE; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; NEOPLASM STAGING; PATIENT SELECTION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 43749093442     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.1804     Document Type: Note

References (30)

1. Fisher B, Redmond C, Brown A, et al: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1:227-241, 1983
2. Fisher B, Wickerham DL, Brown A, et al: Breast cancer estrogen and progesterone receptor values: Their distribution, degree of concordance, and relation to number of positive axillary nodes. J Clin Oncol 1:349-358, 1983
3. Fisher B, Ravdin RG, Ausman RK, et al: Surgical adjuvant chemotherapy in cancer of the breast: Results of a decade of cooperative investigation. Ann Surg 168:337-356, 1968
4. Fisher B, Slack NH: Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 131:79-88, 1970
5. Fisher B: The surgical dilemma in the primary therapy of invasive breast cancer: A critical appraisal. Curr Probl Surg Oct:3-53, 1970
6. Fisher B, Slack NH, Bross IDJ, et al: Cancer of the breast: Size of neoplasm and prognosis. Cancer 24:1071-1080, 1969
7. Fisher B: Laboratory and clinical research in breast cancer-a personal adventure: The David A. Karnofsky Memorial Lecture. Cancer Res 40:3863-3874, 1980
8. Margottini M, Bucalossi P: El metastasi lymphoghiandolari mammario interne nel cancro della mammella. Boll Oncologia 23:2, 1949
9. Fisher B, Slack NH, Ausman RK, et al: Location of breast carcinoma and prognosis. Surg Gynecol Obstet 129:705-716, 1969
10. DeSombre ER: Estrogens, receptors and cancer: The scientific contributions of Elwood Jensen. Prog Clin Biol Res 332:17-29, 1990
11. Jordan VC: The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole. Breast Cancer Res Treat 11:197-209, 1988
12. Cole MP, Jones CT, Todd ID: A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25:270-275, 1971
13. Ward HWC: Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels. BMJ 1:13-14, 1973
14. Lerner HJ, Band PR, Israel L, et al: Phase II study of tamoxifen: Report of 74 patients with stage IV breast cancer. Cancer Treat Rep 60:1431-1435, 1976
15. Fisher B, Carbone P, Economou SG, et al: L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med 292:117-122, 1975
16. Wittliff JL, Fisher B, Durant JR: Establishment of uniformity in steroid receptor analyses used in cooperative clinical trials of breast cancer treatment, in B. Henningsen, F. Linder, C. Steichele (eds): Recent Results In Cancer Research, Vol 71. Berlin, Germany, Springer-Verlag, 1980, pp 198-206
17. Fisher B, Redmond C, Brown A, et al: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1-6, 1981
18. Cardoso F, Dal Lago L, Braga S: Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself. Int J Gynecol Cancer 16:533-537, 2006 (suppl 2)
19. Fisher B, Redmond C, Wickerham DL, et al: Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy. Br Cancer Res Treat 3:355-364, 1983
20. Fisher ER, Redmond CK, Liu H, et al: Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 45:349-353, 1980
21. Fisher ER, Osborne CK, McGuire WL, et al: Correlation of primary breast cancer histopathology and estrogen receptor content. Br Cancer Res Treat 1:37-41, 1981
22. Fisher B, Fisher ER, Redmond C, et al: Tumor nuclear grade, estrogen receptor, and progesterone receptor: Their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Br Cancer Res Treat 7:147-160, 1986
23. Fisher B, Redmond C, Dimitrov NV, et al: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320:473-478, 1989
24. Fisher B, Dignam J, Mamounas EP, et al: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 14:1982-1992, 1996
25. Fisher B, Anderson S, Tan-Chiu E, et al: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931-942, 2001
26. Fisher B, Jeong J-H, Anderson S, Wolmark N: Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: Updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. JNCI 96:1823-1831, 2004
27. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
28. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. JNCI 89:1673-1682, 1997
29. Fisher B, Jeong J-H, Bryant J, et al: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364:858-868, 2004
30. Fisher B, Fisher ER: The biology of metastasis, in John H. Davis (eds): Current Concepts in Surgery. New York, NY, McGraw Hill Book Company Inc, 1965, pp 321-351